RxDoctor Payments Data

Joanna Sampson, MD

Gastroenterology · Bristol, CTNPI 1124183074

Payments from drug & device makers

$3,909in general payments, 2019–2025

Across 198 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$569
  • Takeda Pharmaceuticals U.S.A., Inc.$467
  • Phathom Pharmaceuticals, Inc.$433
  • Johnson & Johnson$423
  • Sanofi$110
  • plus $670 from 16 others

What the payments were for

  • Food & beverage$3,892100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,909 in reported general payments places this provider in the 50th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$145,098
Medicare patients
636
Services billed
891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab25$634,896
Skyrizi On-BodyRisankizumab-Rzaa17$342,022
Humira(Cf) PenAdalimumab25$230,819
RinvoqUpadacitinib13$81,128
LinzessLinaclotide66$49,509
Mesalamine57$40,225
TrulancePlecanatide41$35,546
Budesonide EcBudesonide21$14,244
Ursodiol30$9,038
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C54$7,629
AprisoMesalamine11$6,460
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl392$5,948
Mesalamine ErMesalamine27$5,798
Omeprazole327$5,385
ClenpiqSod Picosulf/Mag Ox/Citric Ac22$3,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$423$634,89625 claims
AbbVieRinvoq, Linzess$1,237$130,63779 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu, Apriso$569$49,635106 claims
Ferring Pharmaceuticals Inc.Clenpiq$16$3,78922 claims
SandozLansoprazole$19$23920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Bristol

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →